Sarah A Keim1,2,3, Barbara Gracious4,5,6, Kelly M Boone1, Mark A Klebanoff7,2,8,3, Lynette K Rogers7,2, Joseph Rausch1,2, Daniel L Coury2,6, Kelly W Sheppard1, Jesse Husk1, Dale A Rhoda9. 1. Centers for Biobehavioral Health, Innovation in Pediatric Practice, and Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH. 2. Departments of Pediatrics, Psychiatry and Behavioral Health, and Obstetrics and Gynecology, College of Medicine, and Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. 3. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. 4. Centers for Innovation in Pediatric Practice, and Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH. 5. Psychiatry and Behavioral Health, and Obstetrics and Gynecology, College of Medicine, and Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. 6. Department of Child and Adolescent Psychiatry and Behavioral Health, Nationwide Children's Hospital, Columbus, OH. 7. Centers for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH. 8. Departments of Obstetrics and Gynecology, College of Medicine, and Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. 9. Biostat Global Consulting, Worthington, OH.
Abstract
Background: Children born preterm are at increased risk of autism spectrum disorder (ASD). n-3 (ω-3) Combined with n-6 (ω-6) fatty acids including γ-linolenic acid (GLA) may benefit children born preterm showing early signs of ASD. Previous trials have reported that docosahexaenoic acid (DHA) promotes cognitive development in preterm neonates and n-3 fatty acids combined with GLA improve attention-deficit-hyperactivity disorder. Objectives: The objectives of the pilot Preemie Tots Trial were 1) to confirm the feasibility of a full-scale trial in toddlers born very preterm and exhibiting ASD symptoms and 2) to explore the effects of supplementation on parent-reported ASD symptoms and related behaviors. Methods: This was a 90-d randomized, fully blinded, placebo-controlled trial in 31 children 18-38 mo of age who were born at ≤29 wk of gestation. One group was assigned to daily Omega-3-6-9 Junior (Nordic Naturals, Inc.) treatment (including 338 mg eicosapentaenoic acid, 225 mg DHA, and 83 mg GLA), and the other group received canola oil (124 mg palmitic acid, 39 mg stearic acid, 513 mg linoleic acid, 225 mg α-linolenic acid, and 1346 mg oleic acid). Mixed-effects regression analyses followed intent-to-treat analysis and explored effects on parent-reported ASD symptoms and related behaviors. Results: Of 31 children randomly assigned, 28 had complete outcome data. After accounting for baseline scores, those assigned to treatment exhibited a greater reduction in ASD symptoms per the Brief Infant Toddler Social Emotional Assessment ASD scale than did those assigned to placebo (difference in change = - 2.1 points; 95% CI: - 4.1, - 0.2 points; standardized effect size = - 0.71). No other outcome measure reflected a similar magnitude or a significant effect. Conclusions: This pilot trial confirmed adequate numbers of children enrolled and participated fully in the trial. No safety concerns were noted. It also found clinically-significant improvements in ASD symptoms for children randomly assigned to receive Omega-3-6-9 Junior, but effects were confined to one subscale. A future full-scale trial is warranted given the lack of effective treatments for this population. This trial was registered at www.clinicaltrials.gov as NCT01683565.
RCT Entities:
Background: Children born preterm are at increased risk of autism spectrum disorder (ASD). n-3 (ω-3) Combined with n-6 (ω-6) fatty acids including γ-linolenic acid (GLA) may benefit children born preterm showing early signs of ASD. Previous trials have reported that docosahexaenoic acid (DHA) promotes cognitive development in preterm neonates and n-3 fatty acids combined with GLA improve attention-deficit-hyperactivity disorder. Objectives: The objectives of the pilot Preemie Tots Trial were 1) to confirm the feasibility of a full-scale trial in toddlers born very preterm and exhibiting ASD symptoms and 2) to explore the effects of supplementation on parent-reported ASD symptoms and related behaviors. Methods: This was a 90-d randomized, fully blinded, placebo-controlled trial in 31 children 18-38 mo of age who were born at ≤29 wk of gestation. One group was assigned to daily Omega-3-6-9 Junior (Nordic Naturals, Inc.) treatment (including 338 mg eicosapentaenoic acid, 225 mg DHA, and 83 mg GLA), and the other group received canola oil (124 mg palmitic acid, 39 mg stearic acid, 513 mg linoleic acid, 225 mg α-linolenic acid, and 1346 mg oleic acid). Mixed-effects regression analyses followed intent-to-treat analysis and explored effects on parent-reported ASD symptoms and related behaviors. Results: Of 31 children randomly assigned, 28 had complete outcome data. After accounting for baseline scores, those assigned to treatment exhibited a greater reduction in ASD symptoms per the Brief Infant Toddler Social Emotional Assessment ASD scale than did those assigned to placebo (difference in change = - 2.1 points; 95% CI: - 4.1, - 0.2 points; standardized effect size = - 0.71). No other outcome measure reflected a similar magnitude or a significant effect. Conclusions: This pilot trial confirmed adequate numbers of children enrolled and participated fully in the trial. No safety concerns were noted. It also found clinically-significant improvements in ASD symptoms for children randomly assigned to receive Omega-3-6-9 Junior, but effects were confined to one subscale. A future full-scale trial is warranted given the lack of effective treatments for this population. This trial was registered at www.clinicaltrials.gov as NCT01683565.
Authors: Maria Makrides; Robert A Gibson; Andrew J McPhee; Carmel T Collins; Peter G Davis; Lex W Doyle; Karen Simmer; Paul B Colditz; Scott Morris; Lisa G Smithers; Kristyn Willson; Philip Ryan Journal: JAMA Date: 2009-01-14 Impact factor: 56.272
Authors: Marc E Surette; Iphigenia L Koumenis; Michelle B Edens; Kenneth M Tramposch; Floyd H Chilton Journal: Clin Ther Date: 2003-03 Impact factor: 3.393
Authors: James M Perrin; Daniel L Coury; Susan L Hyman; Lynn Cole; Ann M Reynolds; Traci Clemons Journal: Pediatrics Date: 2012-11 Impact factor: 7.124
Authors: Bonnie E Stephens; Carla M Bann; Victoria E Watson; Stephen J Sheinkopf; Myriam Peralta-Carcelen; Anna Bodnar; Kimberly Yolton; Ricki F Goldstein; Anna M Dusick; Deanne E Wilson-Costello; Michael J Acarregui; Athina Pappas; Ira Adams-Chapman; Elisabeth C McGowan; Roy J Heyne; Susan R Hintz; Richard A Ehrenkranz; Janell Fuller; Abhik Das; Rosemary D Higgins; Betty R Vohr Journal: J Dev Behav Pediatr Date: 2012-09 Impact factor: 2.225
Authors: Kelly M Boone; Andria Parrott; Joseph Rausch; Keith Owen Yeates; Mark A Klebanoff; Abigail Norris Turner; Sarah A Keim Journal: Pediatrics Date: 2020-09-04 Impact factor: 7.124
Authors: Kelly M Boone; Mark A Klebanoff; Lynette K Rogers; Joseph Rausch; Daniel L Coury; Sarah A Keim Journal: Early Hum Dev Date: 2022-05-19 Impact factor: 2.699
Authors: Sarah A Keim; Abigail Jude; Katie Smith; Aiman Q Khan; Daniel L Coury; Joseph Rausch; Shivika Udaipuria; Megan Norris; Lindsay R Bartram; Anita R Narayanan; Lynette K Rogers Journal: J Autism Dev Disord Date: 2022-01-11
Authors: Kelly W Sheppard; Kelly M Boone; Barbara Gracious; Mark A Klebanoff; Lynette K Rogers; Joseph Rausch; Christopher Bartlett; Daniel L Coury; Sarah A Keim Journal: J Autism Dev Disord Date: 2017-11
Authors: Bo Yang; Runting Li; Taeseon Woo; Jimmy D Browning; Hailong Song; Zezong Gu; Jiankun Cui; James C Lee; Kevin L Fritsche; David Q Beversdorf; Grace Y Sun; C Michael Greenlief Journal: Metabolites Date: 2019-03-01
Authors: Gian Loreto D'Alò; Franco De Crescenzo; Silvia Minozzi; Gian Paolo Morgano; Zuzana Mitrova; Maria Luisa Scattoni; Laura Amato; Marina Davoli; Holger J Schünemann Journal: Health Qual Life Outcomes Date: 2020-04-16 Impact factor: 3.186
Authors: Franco De Crescenzo; Gian Loreto D'Alò; Gian Paolo Morgano; Silvia Minozzi; Zuzana Mitrova; Rosella Saulle; Fabio Cruciani; Francesca Fulceri; Marina Davoli; Maria Luisa Scattoni; Francesco Nardocci; Holger Jens Schünemann; Laura Amato Journal: Health Qual Life Outcomes Date: 2020-02-17 Impact factor: 3.186